Literature DB >> 15073283

Regulation of Fas ligand expression by vascular endothelial growth factor in endometrial stromal cells in vitro.

M Berkkanoglu1, O Guzeloglu-Kayisli, U A Kayisli, B F Selam, A Arici.   

Abstract

When Fas ligand (FasL) interacts with the Fas receptor, it induces apoptosis through autocrine and/or paracrine signalling. Vascular endothelial growth factor (VEGF) is a potent mitogenic cytokine. VEGF plays a role during remodelling of the endometrium following menstruation. We hypothesized that, by regulating FasL expression, VEGF may play a role in endometrial stromal cell survival by decreasing autocrine apoptotic signalling. We aimed to determine the expression of FasL in cultured endometrial stromal cells and its modulation by VEGF. VEGF induced a decrease in both FasL-positive cell number and FasL intensity as determined by immunocytochemistry and western blot respectively (P < 0.05). These effects of VEGF were observed in a concentration-dependent manner (10-42%; P < 0.05). Anti-VEGF neutralizing antibody alone resulted in an increase in the FasL expression. When combined with VEGF, anti-VEGF reversed the VEGF-induced decrease in FasL level up to 100% (P < 0.05). In addition, western blot analysis showed that FasL expression in endometrial stromal cells demonstrated a cyclic change every 12 h during 48 h of incubation. These results suggest that down-regulation of FasL by VEGF may affect endometrial stromal cell survival in an autocrine or paracrine manner. The decrease in FasL level may be due to a stimulation of its degradation. Our results show that FasL in endometrial stromal cells in culture has a cyclic expression model, suggesting that there may be a regulation at the translation level.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15073283     DOI: 10.1093/molehr/gah060

Source DB:  PubMed          Journal:  Mol Hum Reprod        ISSN: 1360-9947            Impact factor:   4.025


  2 in total

1.  A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia.

Authors:  Andrew C Dudley; David Thomas; James Best; Alicia Jenkins
Journal:  Biochem J       Date:  2005-09-01       Impact factor: 3.857

2.  Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib.

Authors:  Atsushi Ono; Hiroshi Aikata; Masami Yamauchi; Kenichiro Kodama; Waka Ohishi; Takeshi Kishi; Kazuki Ohya; Yuji Teraoka; Mitsutaka Osawa; Hatsue Fujino; Takashi Nakahara; Eisuke Murakami; Daiki Miki; Tomokazu Kawaoka; Hiromi Abe-Chayama; Peiyi Zhang; Songyao Liu; Grace Naswa Makokha; Masataka Tsuge; Michio Imamura; C Nelson Hayes; Kazuaki Chayama
Journal:  Ther Adv Med Oncol       Date:  2020-05-20       Impact factor: 8.168

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.